QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019

QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019

Background: Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). Objective: The arrhythmic safety profile of HCQ monotherapy, which remains under i...

Description complète

Détails bibliographiques
Auteurs principaux: Arun R. Sridhar, MBBS, MPH, Neal A. Chatterjee, MD, MSc, Basil Saour, MD, Dan Nguyen, MD, Elizabeth A. Starnes, ARNP, Christine Johnston, MD, MPH, Margaret L. Green, MD, MPH, Gregory A. Roth, MD, Jeanne E. Poole, MD, FHRS
Format: Article
Langue:English
Publié: Elsevier 2020-08-01
Collection:Heart Rhythm O2
Sujets:
Coronavirus
Electrocardiogram
Hydroxychloroquine
QT interval
Ventricular arrhythmia
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2666501820300751

Internet

http://www.sciencedirect.com/science/article/pii/S2666501820300751

Documents similaires